CN116898917A - Liver-protecting pharmaceutical composition and application thereof - Google Patents
Liver-protecting pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN116898917A CN116898917A CN202310900692.4A CN202310900692A CN116898917A CN 116898917 A CN116898917 A CN 116898917A CN 202310900692 A CN202310900692 A CN 202310900692A CN 116898917 A CN116898917 A CN 116898917A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- liver
- extraction
- chrysanthemum
- medlar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 76
- 210000004185 liver Anatomy 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 210000000582 semen Anatomy 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 31
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 244000010000 Hovenia dulcis Species 0.000 claims description 19
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 19
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 18
- 244000182216 Mimusops elengi Species 0.000 claims description 18
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 18
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 18
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 18
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 18
- 244000046146 Pueraria lobata Species 0.000 claims description 17
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims description 17
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims description 17
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- -1 pH regulator Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 241000723353 Chrysanthemum Species 0.000 claims 5
- 240000000038 Ziziphus mauritiana Species 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 abstract description 10
- 230000036542 oxidative stress Effects 0.000 abstract description 7
- 241000628997 Flos Species 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000003908 liver function Effects 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 20
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 18
- 206010067125 Liver injury Diseases 0.000 description 16
- 231100000753 hepatic injury Toxicity 0.000 description 15
- 210000005228 liver tissue Anatomy 0.000 description 10
- 210000004969 inflammatory cell Anatomy 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000035622 drinking Effects 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 244000241872 Lycium chinense Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000015459 Lycium barbarum Nutrition 0.000 description 3
- 235000015468 Lycium chinense Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 235000008586 Hovenia Nutrition 0.000 description 2
- 241000405398 Hovenia Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241000219100 Rhamnaceae Species 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 235000010955 Hovenia acerba Nutrition 0.000 description 1
- 241001533134 Hovenia acerba Species 0.000 description 1
- 235000009229 Hovenia trichocarpa Nutrition 0.000 description 1
- 241000724121 Hovenia trichocarpa Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000731396 Pueraria montana var. thomsonii Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for protecting liver and application thereof. The raw material medicines of the pharmaceutical composition comprise: radix Puerariae, semen Hoveniae, pericarpium Citri Tangerinae, flos Chrysanthemi, fructus Jujubae and fructus Lycii. The invention can improve liver function, reduce damage of drugs, alcohol or viruses to liver cells, inhibit oxidative stress of liver cells, and the like. In addition, the invention has the characteristics of safety, low toxicity, good drug effect and the like, and can condition the whole body and improve the immunity of patients.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a medicinal composition for protecting liver and application thereof.
Background
Liver is the largest metabolic organ of the human body and mainly metabolizes various substances such as sugar, protein, lipid, etc. in three ways of synthesis, decomposition and transformation. The liver is also the largest detoxication organ of human body, and its main function is to remove toxin in body, and the toxin is discharged out of body through metabolic transformation after detoxication. With the continuous improvement of the living standard of people and the improvement of the attention of people to the health of the people, the incidence rate of some liver injury diseases is also increased year by year. For example: viral hepatitis, drug-induced liver injury, alcoholic liver disease, etc. After liver injury, the body will have a series of symptoms such as inappetence, nausea, vomiting, abdominal distension and the like, and part of patients may have liver discomfort or pain. Further exacerbation of liver injury would be expected if not treated in time. Liver damage is a common pathological basis for a variety of liver diseases, and can cause cirrhosis, liver fibrosis and even liver cancer. The occurrence and development of liver diseases are closely related to various factors (such as cytokines, endotoxin, etc.), and lipid peroxidation are important causes of occurrence and development of liver diseases.
In recent years, intensive research on chemical substances for inducing liver injury has been conducted, and it is found that the chemical substances can induce various cells, tissues and organs to generate inflammatory reactions, oxidative stress, liver fibrosis and other pathological changes, and the liver injury needs to be relieved by regulating extracellular matrix protein levels, activating apoptosis, promoting liver regeneration and other mechanisms.
The western medicine does not achieve satisfactory curative effects on liver diseases, so prevention, treatment and prognosis intervention of liver diseases by adopting traditional Chinese medicines become a hotspot of current liver disease research.
Disclosure of Invention
In order to more effectively utilize traditional Chinese medicines to prevent, treat and prognosis liver diseases of patients, improve liver conditions of the patients and improve life quality of the patients. The invention is realized by the following technical scheme.
In a first aspect, the present invention provides a liver protecting pharmaceutical composition, which comprises kudzuvine root, hovenia dulcis thunb, dried orange peel, chrysanthemum, jujube and wolfberry fruit as raw material medicaments.
Preferably, the pharmaceutical composition comprises the following bulk drugs in parts by weight: 10-50g of kudzuvine root, 10-50g of hovenia dulcis thunb, 5-40g of dried orange peel, 5-40g of chrysanthemum, 5-40g of Chinese date and 5-40g of medlar.
Preferably, the pharmaceutical composition comprises the following bulk drugs in parts by weight: 10-30g of kudzuvine root, 10-30g of hovenia dulcis thunb, 5-20g of dried orange peel, 5-20g of chrysanthemum, 5-20g of Chinese date and 5-20g of medlar.
Preferably, the pharmaceutical composition comprises the following bulk drugs in parts by weight: 15g of kudzuvine root, 15g of hovenia dulcis thunb, 10g of dried orange peel, 10g of chrysanthemum, 10g of Chinese date and 10g of medlar.
In a second aspect, the present invention provides another liver protecting pharmaceutical composition consisting of kudzuvine root, hovenia dulcis thunb, dried orange peel, chrysanthemum, date and wolfberry fruit.
Preferably, the pharmaceutical composition comprises 10-50g of kudzuvine root, 10-50g of hovenia dulcis thunb, 5-40g of dried orange peel, 5-40g of chrysanthemum, 5-40g of Chinese date and 5-40g of medlar.
Further preferably, the pharmaceutical composition is composed of 10-30g of kudzuvine root, 10-30g of hovenia dulcis thunb, 5-20g of dried orange peel, 5-20g of chrysanthemum, 5-20g of Chinese date and 5-20g of medlar.
More preferably, the pharmaceutical composition is composed of 15g of kudzuvine root, 15g of hovenia dulcis thunb, 10g of dried orange peel, 10g of chrysanthemum, 10g of Chinese date and 10g of medlar.
In a specific embodiment of the present invention, the pharmaceutical composition further includes pharmaceutically acceptable auxiliary materials, where the auxiliary materials are selected from preservatives, colorants, pH adjusters, buffers, antioxidants, metal ion chelating agents, bacteriostats, isotonicity adjusters, carriers, diluents, binders, lubricants, sweeteners, absorbents, disintegrants, wetting agents, fillers, flavoring agents, and capsule shells.
Further preferably, the filler comprises: starch, sugar, dextrin, microcrystalline cellulose MCC, and the like.
Further preferably. The wetting agent comprises: distilled water, starch slurry, powdered sugar, syrup, microbial derivatives, and the like.
Further preferably, the lubricant comprises: magnesium stearate, oxidized vegetable oil, polyethylene glycol, and the like.
Further preferably, the flavoring agent comprises: sucrose, stevioside, syrup, peppermint water, cassia oil, gelatin, citric acid and the like.
Further preferably, the capsule wall material for capsules comprises: chitosan, proteins, cyclodextrins, galactose, etc.
In one embodiment of the present invention, the above pharmaceutical composition is selected from: decoction, powder, oral liquid, tablet, capsule, pill, injection, inhalant, suppository, emulsion, nanoparticle, gel, powder, suspension, cream, jelly, and spray.
In one specific embodiment of the invention, the pharmaceutical composition is prepared by mixing extracts after each raw material medicine is extracted respectively, or is prepared by mixing and extracting each raw material medicine.
Preferably, the extraction method of the pharmaceutical composition is selected from: solvent extraction, percolation, decoction, reflux, ultrasonic extraction or supercritical fluid extraction.
In a third aspect, the present invention provides a process for the preparation of a pharmaceutical composition according to the first and second aspects, comprising the steps of:
step 1, weighing radix puerariae, semen hoveniae, dried orange peel, chrysanthemum, chinese date and medlar according to the formula of the pharmaceutical composition, putting the mixture into a pulverizer to be pulverized into powder, sieving the powder with a 60-mesh sieve, mixing the powder uniformly, and adding water for soaking;
step 2, placing the soaked medicinal composition into a flask of a microwave extraction instrument, and performing microwave extraction under the conditions of microwave power of 300-400W, extraction temperature of 40-50 ℃ and heating time of 3 min;
step 3, heating and refluxing the medicine composition after microwave extraction, filtering and collecting filtrate, and adding residues into water; and then heating and refluxing for the second time, filtering, collecting filtrate, combining the two filtrates, and concentrating to obtain the pharmaceutical composition.
Preferably, the amount of water added in step 1 is 8-12 times, e.g. 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, relative to the total weight of the pharmaceutical composition.
Preferably, the water may be at least one of tap water, purified water or distilled water.
Preferably, the heating reflux time in step 3 is 20-40 minutes, e.g. 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes.
Preferably, the concentration in step 3 is performed by concentrating the combined filtrates by decoction or rotary evaporation, and more preferably by rotary evaporation.
Preferably, the concentration of the pharmaceutical composition obtained in step 3 is 1-10g/mL, e.g. 1g/mL, 2g/mL, 3g/mL, 4g/mL, 5g/mL, 6g/mL, 7g/mL, 8g/mL, 9g/mL, 10g/mL.
In a fifth aspect, the present invention provides the use of a pharmaceutical composition according to the first and second aspects for the manufacture of a medicament for protecting the liver.
Preferably, the pharmaceutical composition can be used for liver injury caused by chemical drugs, liver injury caused by alcohol, liver injury caused by viruses, and the like.
The invention has the beneficial effects that:
1. the invention can improve liver function, reduce damage of drugs, alcohol or viruses to liver cells, inhibit oxidative stress of liver cells, and the like.
2. The invention has the characteristics of safety, low toxicity, good drug effect and the like, and can condition the whole body and improve the immunity of patients.
Drawings
FIG. 1 shows HE staining (x 200) of liver tissue from CCl-induced liver injury mice. Wherein A: blank group; b: a model group; c: a positive control group; d: low dose group; e: medium dose group; f: a high dose group;
in the figure, the arrows indicate inflammatory cells, and the circles indicate necrotic hepatocytes.
Detailed Description
The technical scheme of the present invention will be further described with reference to the following examples and the accompanying drawings, and advantages and features of the present invention will be more apparent with the description. It should be understood that the embodiments are illustrative only and should not be taken as limiting the scope of the invention.
The experimental methods used in the following examples are conventional in the art unless otherwise specified.
According to the theory of traditional Chinese medicine, the invention takes detoxification and liver protection as a treatment principle, and combines kudzuvine root, hovenia dulcis thunb, dried orange peel, chrysanthemum, chinese date and medlar into a pharmaceutical composition for preventing, treating or prognostic intervention liver injury. The principal drugs in the medicine composition are radix puerariae and semen hoveniae, and have the liver detoxification efficacy; the ministerial drugs are dried orange peel and chrysanthemum, and have the effect of clearing liver; the adjuvant drug is medlar, and has the effect of nourishing liver; the Chinese medicinal composition is fructus Jujubae, and has liver nourishing effect.
The medicinal materials used for the pharmaceutical composition of the invention are as follows:
radix Puerariae: dried root of kudzu Pueraria lobata (Willd.) Ohwi or Pueraria thomsonii Pueraria thomsonii Benth of Leguminosae. Sweet and pungent in flavor, cool in nature, has the actions of relieving muscle and fever, promoting eruption, promoting salivation to quench thirst, ascending yang and relieving diarrhea.
Semen Hoveniae: hovenia dulcis Thuneb. Hovenia acerba Lindl. Hovenia dulcis Thuner. Hovenia of Rhamnaceae and Hovenia dulcis Hovenia trichocarpa Chun et Tsiang, hovenia dullness, sweet and sour taste, and the effects of clearing heat and promoting urination, relieving restlessness and quenching thirst, moistening five viscera and dispelling alcohol effect by entering heart and spleen meridians.
Dried orange peel: the dry mature pericarp of Rutaceae plant orange Citrus reticulata Blanco and its cultivar has bitter and pungent taste, warm nature and no toxicity. Enters the liver, spleen and lung meridians. Has effects in regulating liver qi movement and maintaining liver normal physiological function.
And (3) chrysanthemum: (Dendranthema morifolium, latin Flos Chrysanthemi) the petals of perennial herbs of Compositae are tongue or cylindrical, and the chrysanthemum is sweet, slightly bitter and cool, enters liver and lung channels, and has the effects of suppressing hyperactive liver, improving eyesight, clearing heat, dispelling wind, promoting salivation and quenching thirst.
Jujube: mature fruit of jujube of Rhamnaceae has effects of invigorating spleen and replenishing qi, nourishing blood and tranquillizing.
Wolfberry fruit: mature fruits of Lycium chinense Lycium chinense Miller belonging to Solanaceae are sweet in nature, calm, enter liver and kidney meridians, and have effects of nourishing liver and kidney.
Example 1 preparation of pharmaceutical composition sample 1
The bulk drugs of the pharmaceutical composition of the embodiment are composed of 15g of kudzuvine root, 15g of hovenia dulcis thunb, 10g of dried orange peel, 10g of chrysanthemum, 10g of Chinese date and 10g of medlar by weight.
The preparation method of the pharmaceutical composition comprises the following steps:
(1) Mixing radix Puerariae, semen Hoveniae, pericarpium Citri Tangerinae, flos Chrysanthemi, fructus Jujubae and fructus Lycii respectively according to weight, adding 10 times of water of the Chinese medicinal materials mixture, and soaking for 30 min;
(2) Placing the soaked medicinal composition into a flask of a microwave extraction instrument, and performing microwave extraction under the conditions of microwave power of 300-400W, extraction temperature of 40-50 ℃ and heating time of 3 min;
(3) Reflux-heating the medicinal composition after microwave extraction for 25 min, filtering to collect filtrate, and adding the residue into water; then heating and refluxing for 25 minutes twice, filtering, collecting filtrate, combining the two filtrates, concentrating by rotary evaporation until the concentration of the liquid medicine is 3g/mL, obtaining a medicinal composition sample 1, placing the medicinal composition sample 1 at a proper temperature, and drinking the medicinal composition sample for 7 days.
Example 2 preparation of a sample of pharmaceutical composition 2
The bulk drugs of the pharmaceutical composition of the embodiment are composed of 50g of kudzuvine root, 50g of hovenia dulcis thunb, 40g of dried orange peel, 40g of chrysanthemum, 40g of Chinese date and 40g of medlar by weight.
The preparation method of the pharmaceutical composition comprises the following steps:
(1) Mixing radix Puerariae, semen Hoveniae, pericarpium Citri Tangerinae, flos Chrysanthemi, fructus Jujubae and fructus Lycii respectively according to weight, adding 12 times of water, and soaking for 30 min;
(2) Placing the soaked medicinal composition into a flask of a microwave extraction instrument, and performing microwave extraction under the conditions of microwave power of 300-400W, extraction temperature of 40-50 ℃ and heating time of 3 min;
(3) Reflux-heating the medicinal composition after microwave extraction for 40 min, filtering to collect filtrate, and adding the residue into water; then heating and refluxing for 40 minutes for the second time, filtering, collecting filtrate, combining the two filtrates, concentrating by rotary evaporation until the concentration of the liquid medicine is 10g/mL, obtaining the pharmaceutical composition 2, and placing the pharmaceutical composition 2 at a proper temperature for drinking for 7 days.
Example 3 preparation of pharmaceutical composition sample 3
The bulk drugs of the pharmaceutical composition of the embodiment are composed of 10g of kudzuvine root, 10g of hovenia dulcis thunb, 5g of dried orange peel, 5g of chrysanthemum, 5g of Chinese date and 5g of medlar by weight.
The preparation method of the pharmaceutical composition comprises the following steps:
(1) Mixing radix Puerariae, semen Hoveniae, pericarpium Citri Tangerinae, flos Chrysanthemi, fructus Jujubae and fructus Lycii respectively according to weight, adding 8 times of water, and soaking for 30 min;
(2) Placing the soaked medicinal composition into a flask of a microwave extraction instrument, and performing microwave extraction under the conditions of microwave power of 300-400W, extraction temperature of 40-50 ℃ and heating time of 3 min;
(3) Reflux-heating the medicinal composition after microwave extraction for 20 min, filtering to collect filtrate, and adding the residue into water; then heating and refluxing for 20 minutes for the second time, filtering, collecting filtrate, combining the two filtrates, concentrating by rotary evaporation until the concentration of the liquid medicine is 1g/mL, obtaining a medicinal composition sample 3, placing the medicinal composition sample 3 at a proper temperature for drinking, and continuously drinking for 7 days.
Example 4 preparation of pharmaceutical composition sample 4
The bulk drugs of the pharmaceutical composition of the embodiment are composed of 30g of kudzuvine root, 30g of hovenia dulcis thunb, 20g of dried orange peel, 20g of chrysanthemum, 20g of Chinese date and 20g of medlar by weight.
The preparation method of the pharmaceutical composition comprises the following steps:
(1) Mixing radix Puerariae, semen Hoveniae, pericarpium Citri Tangerinae, flos Chrysanthemi, fructus Jujubae and fructus Lycii respectively according to weight, adding 11 times of water, and soaking for 30 min;
(2) Placing the soaked medicinal composition into a flask of a microwave extraction instrument, and performing microwave extraction under the conditions of microwave power of 300-400W, extraction temperature of 40-50 ℃ and heating time of 3 min;
(3) Reflux-heating the medicinal composition after microwave extraction for 30 min, filtering to collect filtrate, and adding the residue into water; then heating and refluxing for 30 minutes for the second time, filtering, collecting filtrate, combining the two filtrates, concentrating by rotary evaporation until the concentration of the liquid medicine is 5g/mL, obtaining a medicinal composition sample 4, placing the medicinal composition sample 4 at a proper temperature for drinking, and continuously drinking for 7 days.
EXAMPLE 5 pharmacodynamic experiments of pharmaceutical compositions
1. Materials and methods
1.1 acute CCl in mice 4 Preparation and administration of oily solution liver injury model
Male mice of the class SPF Kunming species were randomly assigned to body massIs a blank control group, a model group, a positive control group and a high, medium and low dose group of the drug composition. After grouping, each group of mice was numbered with picric acid solution, re-weighed and the weights of the mice were recorded as numbered. After normal feeding of mice for 5 days, the high (18.2 g/kg. BW), medium (9.1 g/kg. BW) and low (4.55 g/kg. BW) dose groups were given daily gavage of the corresponding dose of pharmaceutical composition sample 1. The blank control group and the model group are filled with the double distilled water with the same amount, and the positive control group is filled with the bifendate water solution with the dosage of 150 mg/kg.BW, and the administration volume is 0.02mL/g. The administration was continued for 7d according to the protocol described above. After the seventh day of administration, 0.3% CCl of 0.01mL/g was injected into the abdominal cavity of mice in the high, medium, and low dose groups, the positive control group, and the model group of the pharmaceutical composition at intervals of 2 hours 4 Peanut oil solution mice from the control group were injected with an equal amount of peanut oil solution.
1.2 sample collection
After the mice are fasted and not water-forbidden for 12 hours, weighing, taking blood by using a capillary orbit, dislocation to kill the mice, taking out the livers on an ice table, cleaning, weighing, separating the livers into 2 parts by using surgical scissors, fixing one part by using a 10% formaldehyde solution, and placing the other part into an EP tube and storing in a refrigerator at the temperature of minus 80 ℃.
1.3 index detection
1.3.1 liver index: the livers were removed, the livers were weighed with an electronic balance, and the liver index of each group of mice was calculated: liver index = liver weight/mouse body weight 100%.
1.3.2 liver function index detection: blood was collected and serum was isolated for detection of AST, ALT content.
1.3.3 histopathological examination: the liver was fixed with 10% formaldehyde, paraffin embedded, sectioned, HE stained, and visualized for liver pathology.
1.3.4 detection of tissue oxidative stress index: liver tissue is collected, 0.1g of liver tissue is precisely weighed on an analytical balance, physiological saline is added according to the proportion of 1:9, and 10% tissue homogenate is prepared in a homogenate device to be used as a sample to be tested. Malondialdehyde (MDA), superoxide dismutase (SOD) and GSH activity were detected according to the kit instructions.
1.4 statistical methods
The experimental data were analyzed using SPSS 27.0 software (IBM SPSS 27) and the results were expressed as mean.+ -. Standard error. The differences between groups were tested using one-way analysis of variance (ANOVA) and LSD multiplex comparisons. When P is less than or equal to 0.05, the experimental data is considered to have statistical significance.
2. Experimental results
2.1 pharmaceutical composition vs CCl 4 Influence of liver index in liver-injured mice (see Table 1)
TABLE 1 liver index [ (]n＝9)
Note that: ratio to blank group, < P0.05, < P <0.01 to model group, # P <0.05# # P <0.01
As can be seen from table 1, the liver index was significantly elevated (P < 0.01) with a very significant difference in the model group compared to the blank group. Compared with the model group, the liver index can be reduced to different degrees by different doses of the pharmaceutical composition.
2.2 pharmaceutical composition vs CCl 4 Influence of liver function in liver-damaged mice (see Table 2)
Table 2 mouse serum AST, ALT content (' x+ -s, n=6, U/L)
Note that: ratio to blank group, < P0.05, < P <0.01 to model group, # P <0.05# # P <0.01
As can be seen from Table 2, the ALT and AST activities in the serum of mice in the model group were significantly higher than those in the blank group (P < 0.01), and the difference was extremely significant. And mouldCompared with the group, the ALT activity in the serum of mice in the low, medium and high dose groups of the pharmaceutical composition is reduced (P < 0.01). AST activity was reduced to a different extent than in the model group, wherein AST activity was significantly reduced (P < 0.05) in the low and high dose groups, and experimental data indicate that the pharmaceutical composition was able to reduce CCl 4 AST and ALT levels in serum of liver-injured mice for CCl 4 The liver injury is caused to have a certain protection effect.
2.3 pharmaceutical composition vs CCl 4 Influence of oxidative stress index on liver tissue of liver injury mice (see Table 3)
Table 3 content of mouse liver SOD, GSH, MDA (' x±s, n=6)
Note that: ratio to blank group, < P0.05, < P <0.01 to model group, # P <0.05# # P <0.01
As can be seen from table 3, the mice in the model group had decreased SOD and GSH and increased MDA in liver tissue compared to the blank group. Compared with the model group, the SOD in the liver tissue of the mice in the dose group in the pharmaceutical composition is obviously increased (P < 0.05), the MDA is obviously decreased (P < 0.05), and the GSH in the liver tissue of the mice in the high dose group in the pharmaceutical composition is obviously increased (P < 0.01). The medicine composition has the functions of resisting oxidative stress and relieving lipid peroxidation injury on liver tissues, wherein the medium-high dose group has better effect.
2.4 pharmaceutical composition vs CCl 4 Influence of liver histopathology in liver-injured mice (see FIG. 1)
As shown in fig. 1, the normal group of hepatocytes were morphologically normal and arranged radially around the central vein, and the hepatic lobule, the sink region, and the pericentral vein were clear and intact in their structures, with no inflammatory cell infiltration. The hepatocytes in the central vein and the manifold area of the model group were swollen and necrotized, and the arrangement was irregular. There is a large number of inflammatory cell infiltrates around the central vein and the collecting duct region. The positive control group had hepatic cell necrosis around the central vein and the manifold area and had a smaller or closed pore size, the hepatic lobular structure was disordered, and inflammatory cell infiltration was reduced compared to the model group. The low dose group has orderly hepatic cells, a small amount of hepatic cells are necrotic around the central vein, and inflammatory cell infiltration is obviously reduced compared with the model group. The medium dose group had intact liver cells, liver lobules and central vein, the liver cells were arranged radially around the central vein, and inflammatory cell infiltration was reduced compared to the model group. Portions of the central vein and the manifold area of the high dose group had more inflammatory cell infiltrates, but substantially no necrosis of hepatocytes occurred.
As can be seen from fig. 1, the doses of the pharmaceutical composition inhibited hepatocyte necrosis and inflammatory cell infiltration to varying degrees, with medium doses being evident.
The invention is characterized in that the medicine composition with different dosages is given, and CCl is injected into the abdominal cavity of the mice 4 The oil solution establishes a liver injury model and it was found that different doses of the pharmaceutical composition were able to reduce serum transaminase activity to different extents. Compared with the model group, the serum transaminase of the mice in the pharmaceutical composition group is reduced, which proves that the mice have a certain protective effect on the liver. The pharmaceutical composition can also increase SOD activity in liver tissue, and SOD can catalyze superoxide anion free radical (O) 2- ) Is converted into H without damage to organism 2 O 2 And O 2 The action mechanism of the medicine composition is mainly to remove superoxide anion free radicals harmful to organisms and reduce the damage of the free radicals to liver cells, so that the medicine composition has the effects of inhibiting oxidative stress of the liver cells and enhancing the antioxidation capability of the liver cells. The observation of liver pathology shows that necrotic cells and inflammatory cells in the liver tissue of the mice in the pharmaceutical composition group are obviously reduced compared with the model group, which proves that the pharmaceutical composition can reduce the inflammatory reaction of the liver cells and improve CCl 4 The liver pathological injury caused by the method has a protective effect on the liver injury of mice caused by CCl.
The foregoing description is only illustrative of the present invention and is not intended to limit the scope of the invention, and all equivalent structural changes made by the content of the present invention or direct or indirect application in other related technical fields are included in the scope of the present invention.
Claims (10)
1. A pharmaceutical composition for protecting the liver, characterized in that: the raw material medicines of the pharmaceutical composition comprise radix puerariae, semen hoveniae, dried orange peel, chrysanthemum, chinese date and medlar.
2. The pharmaceutical composition according to claim 1, wherein: the pharmaceutical composition comprises the following raw materials in parts by weight: 10-50g of kudzuvine root, 10-50g of hovenia dulcis thunb, 5-40g of dried orange peel, 5-40g of chrysanthemum, 5-40g of Chinese date and 5-40g of medlar.
3. The pharmaceutical composition according to claim 2, wherein: the pharmaceutical composition comprises the following raw materials in parts by weight: 10-30g of kudzuvine root, 10-30g of hovenia dulcis thunb, 5-20g of dried orange peel, 5-20g of chrysanthemum, 5-20g of Chinese date and 5-20g of medlar.
4. A pharmaceutical composition according to claim 3, characterized in that: the pharmaceutical composition comprises the following raw materials in parts by weight: 15g of kudzuvine root, 15g of hovenia dulcis thunb, 10g of dried orange peel, 10g of chrysanthemum, 10g of Chinese date and 10g of medlar.
5. The pharmaceutical composition according to any one of claims 1-4, wherein: the pharmaceutical composition also comprises pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials are selected from preservative, colorant, pH regulator, buffering agent, antioxidant, metal ion chelating agent, bacteriostat, isotonic regulator, carrier, diluent, adhesive, lubricant, sweetener, absorbent, disintegrating agent and wetting agent.
6. The pharmaceutical composition according to any one of claims 1-4, wherein: the pharmaceutical composition is selected from the group consisting of: decoction, powder, oral liquid, tablet, capsule, pill, injection, inhalant, suppository, emulsion, nanoparticle, gel, powder, suspension, cream, jelly, and spray.
7. The pharmaceutical composition according to any one of claims 1-4, wherein: the medicine composition is prepared by respectively extracting the raw materials and mixing the extracts, or is prepared by mixing the raw materials and extracting.
8. The pharmaceutical composition according to claim 7, wherein: the extraction method of the pharmaceutical composition is selected from the following steps: solvent extraction, percolation, decoction, reflux, ultrasonic extraction or supercritical fluid extraction.
9. The pharmaceutical composition of claim 8, wherein: the extraction method comprises the following steps:
step 1, weighing radix puerariae, semen hoveniae, dried orange peel, chrysanthemum, chinese date and medlar according to the formula of the pharmaceutical composition, putting the mixture into a pulverizer to be pulverized into powder, sieving the powder with a 60-mesh sieve, mixing the powder uniformly, and adding water for soaking;
step 2, placing the soaked medicinal composition into a flask of a microwave extraction instrument, and performing microwave extraction under the conditions of microwave power of 300-400W, extraction temperature of 40-50 ℃ and heating time of 3 min;
step 3, heating and refluxing the medicine composition after microwave extraction, filtering and collecting filtrate, and adding residues into water; and then heating and refluxing for the second time, filtering, collecting filtrate, combining the two filtrates, and concentrating to obtain the pharmaceutical composition.
10. Use of a pharmaceutical composition according to any one of claims 1-9 for the preparation of a medicament for protecting the liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310900692.4A CN116898917A (en) | 2023-07-21 | 2023-07-21 | Liver-protecting pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310900692.4A CN116898917A (en) | 2023-07-21 | 2023-07-21 | Liver-protecting pharmaceutical composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116898917A true CN116898917A (en) | 2023-10-20 |
Family
ID=88359954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310900692.4A Pending CN116898917A (en) | 2023-07-21 | 2023-07-21 | Liver-protecting pharmaceutical composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116898917A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101986876A (en) * | 2009-08-07 | 2011-03-23 | 储愿新 | Drink formula capable of moderating liquor and neutralizing liquor and production process thereof |
| CN103099201A (en) * | 2012-12-11 | 2013-05-15 | 丁杰 | Novel preparation method of acetic fermentation drink |
| CN103479793A (en) * | 2013-09-24 | 2014-01-01 | 青海阿如拉藏医药研究开发有限公司 | Composition for alleviating hangover and protecting liver and preparation method thereof |
| CN104095971A (en) * | 2013-04-10 | 2014-10-15 | 孙冰清 | Traditional Chinese medicine for treating hepatitis |
| CN106900902A (en) * | 2015-12-22 | 2017-06-30 | 史晓强 | A kind of portable Antialcoholic liver-protecting tea bag |
| CN112535230A (en) * | 2020-11-12 | 2021-03-23 | 浙江英格莱制药有限公司 | Herbaceous plant corn peptide vitamin sugar pill and preparation method thereof |
| CN112869152A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of anti-alcohol food |
| CN113456725A (en) * | 2021-06-17 | 2021-10-01 | 浙江天一堂医药管理有限公司 | Product for relieving alcoholism and preparation method thereof |
| CN114521648A (en) * | 2020-11-23 | 2022-05-24 | 辽宁医学诊疗科技研发中心有限公司 | Food composition with auxiliary protection function on chemical liver injury and preparation method thereof |
-
2023
- 2023-07-21 CN CN202310900692.4A patent/CN116898917A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101986876A (en) * | 2009-08-07 | 2011-03-23 | 储愿新 | Drink formula capable of moderating liquor and neutralizing liquor and production process thereof |
| CN103099201A (en) * | 2012-12-11 | 2013-05-15 | 丁杰 | Novel preparation method of acetic fermentation drink |
| CN104095971A (en) * | 2013-04-10 | 2014-10-15 | 孙冰清 | Traditional Chinese medicine for treating hepatitis |
| CN103479793A (en) * | 2013-09-24 | 2014-01-01 | 青海阿如拉藏医药研究开发有限公司 | Composition for alleviating hangover and protecting liver and preparation method thereof |
| CN106900902A (en) * | 2015-12-22 | 2017-06-30 | 史晓强 | A kind of portable Antialcoholic liver-protecting tea bag |
| CN112869152A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of anti-alcohol food |
| CN112535230A (en) * | 2020-11-12 | 2021-03-23 | 浙江英格莱制药有限公司 | Herbaceous plant corn peptide vitamin sugar pill and preparation method thereof |
| CN114521648A (en) * | 2020-11-23 | 2022-05-24 | 辽宁医学诊疗科技研发中心有限公司 | Food composition with auxiliary protection function on chemical liver injury and preparation method thereof |
| CN113456725A (en) * | 2021-06-17 | 2021-10-01 | 浙江天一堂医药管理有限公司 | Product for relieving alcoholism and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 乔海灵, 朱振峰, 张启堂: "康乐宝对氢化可的松所致小鼠阳虚证的对抗作用", 郑州大学学报(医学版), no. 04, 20 December 1995 (1995-12-20), pages 354 - 357 * |
| 李有实;: "葛根解酒软肝胶囊治疗酒精性肝病48例临床观察", 实用中医内科杂志, no. 05, 10 March 2013 (2013-03-10), pages 26 - 27 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108434231A (en) | It is a kind of to resist the liquor-saturated integration of drinking and medicinal herbs Chinese medicine composition and preparation method thereof to relieve the effect of alcohol | |
| CN102078487B (en) | Chinese medicinal preparation for treating vertigo | |
| CN102988905B (en) | Traditional Chinese medicine preparation for treating epilepsia and preparation method thereof | |
| CN101804103B (en) | Drug for treating leukopenia caused by concurrent chemoradiotherapy of malignant tumor and preparation method thereof | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| CN107412665B (en) | It is a kind of that there is Chinese medicine composition for relieving the effect of alcohol, preventing alcoholic liver injury and its preparation method and application | |
| CN116509971A (en) | Traditional Chinese medicine formula, traditional Chinese medicine liquid and medicinal preparation with intelligence improving effect | |
| CN116898917A (en) | Liver-protecting pharmaceutical composition and application thereof | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| CN100428944C (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN112316051B (en) | Traditional Chinese medicine composition for nourishing blood and reducing phlegm as well as traditional Chinese medicine preparation, preparation method and application thereof | |
| CN103301341A (en) | Traditional Chinese medicine composition of treating ischemic cerebral apoplexy | |
| CN1325097C (en) | Liver-protecting detoxification particles for curing drug induced liver injury and its production method | |
| CN1314423C (en) | Kudzuvine root containing capsule capable of regulating blood pressure and blood fat, preventing and treating cardiovascular and cerebrovascular diseases | |
| CN112791150A (en) | Traditional Chinese medicine composition for treating neck vascular plaque and preparation method thereof | |
| CN101439131B (en) | Chinese medicinal composition for treating phonosensitive nerve deafness and use thereof | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN109200191A (en) | Restrain myogenic, Chinese materia medica preparation of light speckles, beautification and white and preparation method thereof | |
| CN116270830B (en) | Anti-radiation traditional Chinese medicine composition and application thereof | |
| CN116549543B (en) | Compound antioxidant product containing American ginseng and preparation method and application thereof | |
| CN115006460B (en) | Traditional Chinese medicine composition for dispelling effects of alcohol and protecting liver as well as preparation method and application thereof | |
| CN111388604B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN102274357A (en) | Pharmaceutical composition for treating coronary arteriosclerotic heart disease and preparation method thereof | |
| CN104491557A (en) | Drug for treating blocking gastrointestinal type type organophosphorus pesticide pesticide intoxication and preparation method for drug | |
| CN115429857A (en) | Traditional Chinese medicine composition for treating mania, medicament and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |